Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05096208 · ClinicalTrials.gov registry record · Phase 3

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

A Phase 3 study of RSV, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
1,028
Enrollment target
18
Study locations

NCT05096208 is a Phase 3 study of RSV that has completed, run by Pfizer. The registered enrollment target is 1,028 participants, below the 142,000-participant average among 3 other RSV trials with a reported enrollment target (99% lower). The trial reports 18 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05096208, a Phase 3 study of RSV, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
1,028 participants
Enrollment target
18
Study locations

Study Summary

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.

Conditions Studied

RSV

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL RSVpreF (Group 1)
  • BIOLOGICAL RSVpreF (Group 2)
  • BIOLOGICAL RSVpreF (Group 3)

Study Locations (18)

Florida

  • Global Health Research Center, Inc. - Miami Lakes
  • Precision Clinical Research - Sunrise
  • Clinical Site Partners, Inc - Winter Park
  • Clinical Site Partners - Winter Park

Texas

  • Benchmark Research - Austin
  • Texas Center for Drug Development, Inc. - Houston
  • DM Clinical Research - Tomball

Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic - Salt Lake City
  • J. Lewis Research, Inc. / Foothill Family Clinic South - Salt Lake City

Georgia

  • Clinical Research Atlanta - Stockbridge

Hawaii

  • East-West Medical Research Institute - Honolulu

Idaho

  • Clinical Research Prime - Idaho Falls

Kentucky

  • Kentucky Pediatric/ Adult Research - Bardstown

Missouri

  • Sundance Clinical Research - St Louis

Trial Details

FieldValue
Enrollment Target 1,028 participants
Start Date 2021-10-21
Est. Completion 2022-04-04
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05096208

The ClinicalTrials.gov registry entry for NCT05096208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,028 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142,000-participant average among 3 other RSV trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with RSV appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT05096208 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Florida, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT05096208 about?

NCT05096208 is a clinical study titled "Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age". This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.

What is the current status of trial NCT05096208?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,028 participants. The study started on 2021-10-21. Estimated completion is 2022-04-04.

What conditions does trial NCT05096208 study?

This clinical trial studies the following conditions: RSV.

What interventions are being tested in trial NCT05096208?

The interventions under investigation include: Placebo (BIOLOGICAL), RSVpreF (Group 1) (BIOLOGICAL), RSVpreF (Group 2) (BIOLOGICAL), RSVpreF (Group 3) (BIOLOGICAL).

Who is sponsoring clinical trial NCT05096208?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05096208 being conducted?

This trial has 18 study locations across Florida, Georgia, Hawaii, Idaho, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for RSV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

RSV

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.